RE: Alas , more evidence our NAV calculations will hold up.30 Apr 2024 09:23
Endomag was one of the companies I had spotted as a solid sign of value before they started including it in the core.
As with a number of other companies in the portfolio they were working to deliver a solution to a well defined problem in this case, an improved diagnostic device for planning operations for breast cancer and preventing unnecessary ones on lymph nodes.
Turned out a good return on the £9m invested. You could see they were a well performing company as they had finance from mainstream lenders for working capital.
Shame they have to be bought by a US company to continue their growth.